Quince Therapeutics (NASDAQ:QNCX) Upgraded by Citizens Jmp to “Outperform” Rating

Quince Therapeutics (NASDAQ:QNCX) was upgraded by Citizens Jmp from a “market perform” rating to an “outperform” rating in a report released on Tuesday, Marketbeat Ratings reports. The firm presently has a $77.00 price objective on the stock. Citizens Jmp’s price objective would suggest a potential upside of 148.39% from the stock’s previous close.

Other research analysts also recently issued reports about the stock. Craig Hallum raised shares of Quince Therapeutics to a “strong-buy” rating in a research report on Thursday, August 27th. Wall Street Zen cut shares of Quince Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Cantor Fitzgerald restated an “overweight” rating and issued a $70.00 price objective on shares of Quince Therapeutics in a research note on Tuesday, August 18th. Oppenheimer initiated coverage on Quince Therapeutics in a report on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price objective on the stock. Finally, Leerink Partners started coverage on Quince Therapeutics in a research report on Wednesday, June 24th. They set an “outperform” rating and a $80.00 target price on the stock. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Quince Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $229.50.

Quince Therapeutics Price Performance

Quince Therapeutics stock opened at $31.00 on Tuesday. The stock has a market cap of $31.62 million, a PE ratio of -0.20 and a beta of 1.31. The stock’s fifty day moving average is $27.71 and its two-hundred day moving average is $23.77. Quince Therapeutics has a 1-year low of $15.10 and a 1-year high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Friday, August 14th. The company reported ($12.31) EPS for the quarter, beating analysts’ consensus estimates of ($28.02) by $15.71.

Hedge Funds Weigh In On Quince Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. acquired a new stake in Quince Therapeutics during the 2nd quarter worth approximately $31,000. Intellectus Partners LLC purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth approximately $179,000. Finally, 683 Capital Management LLC purchased a new stake in shares of Quince Therapeutics during the fourth quarter worth approximately $798,000. Institutional investors and hedge funds own 30.75% of the company’s stock.

About Quince Therapeutics

Quince Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for rare diseases. The company’s research centers on its erythrocyte-derived extracellular vesicle (EEV) platform, which uses patients’ red blood cells to encapsulate and deliver therapeutic compounds.

Quince’s lead investigational product is eDSP, formerly known as EryDex, an autologous red-blood-cell-based formulation of dexamethasone sodium phosphate being developed for ataxia-telangiectasia (A-T).